Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCENT: sintilimab plus chidamide in relapsed/refractory extranodal NK/T-cell lymphoma
ChiCTR1900020748Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Jan 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and tucidinostat in extranodal natural killer/T-cell lymphoma (ENKTL), sponsored by Sun Yat-sen University Cancer Center. Primary endpoints: Objective response rate, Maximum tolerated dose of chidamide and 2 more. Started Jan 2019; status: recruiting.
02
Drugs
sintilimabtucidinostat
03
Conditions
extranodal natural killer/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on ChiCTR1900020748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900020748.